It is trading at $0.50 well above $0.43, the stock’s 50 day moving average and which is marginally over the 200 day moving average of $0.50. The 50 day moving average went up by +15.4164% and the 200 day average was up $0.00. (NASDAQ:RPRX) shares saw light trading volume with 820K shares changing hands in the last trading session. Overall, volume was down 70.18% under the stocks normal daily volume.
Investors are a little more bearish on shares of Repros Therapeutics Inc. recently considering the increase in short interest. The stock realized a rise in short interest of 155.45% between September 29, 2017 and October 13, 2017. Short shares grew 935,678 over that period. With short interest at 1,537,581 and short average daily volume at 3,895,054, the short-interest ratio is 0.0 and the percentage of shorted shares is 0.05% as of October 13.
Here are a few substantial investment firms who have updated their positions. Citadel Advisors LLC cut its investment by shedding 1,300 shares a decrease of 3.4% in the quarter. Citadel Advisors LLC claims 37,200 shares with a value of $17,000. The value of the position overall is down by 63.0%. Creative Planning downsized its stake by selling 100 shares a decrease of 2.0% from 03/31/2017 to 06/30/2017. Creative Planning currently owns 5,000 shares worth $2,000. The total value of its holdings decreased 66.7%.
As of the end of the quarter Ubs Group Ag had disposed of a total of 59 shares trimming its position 37.1%. The value in dollars went from $0 to $0 a change of $0 for the reporting period. As of quarter end Allegis Investment Advisors, LLC had bought 32,602 shares growing its stake by 8.9%. The value of the investment in Repros Therapeutics Inc. decreased from $439,000 to $183,000 a change of 58.3% quarter over quarter.
As of the latest earnings report the EPS was $-0.62 and is estimated to be $-1.07 for the current year with 37,615,000 shares now outstanding. Next quarter’s EPS is forecasted at $-0.32 with next year’s EPS projected to be $-1.01.
Repros Therapeutics, Inc., launched on August 20, 1987, is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Business’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Through its clinical program, the Company is focused on conducting a Phase IIb study for low dose oral Proellex in the treatment of uterine fibroids; conducting a Phase IIb vaginal administration study for Proellex in the treatment of uterine fibroids; conducting a Phase II study for low dose oral Proellex for the treatment of endometriosis, and conducting a Phase II proof of concept study for enclomiphene for the treatment of secondary hypogonadism..